Turn Therapeutics Inc. 8K

Turn Therapeutics appointed former CDC Director Robert R. Redfield, M.D., as its Chief Scientific Officer to lead scientific and clinical strategy for GX-03 and related programs.

On September 9, 2026, Turn Therapeutics Inc. announced that it has appointed Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as its Chief Scientific Officer, where he will lead and contribute to the scientific and clinical strategy for the company’s lead candidate GX-03 across multiple inflammatory and infectious skin disease indications and work closely with the CEO and other senior scientific leaders to guide program development and future indications.

Filing Facts

CIK

2023016

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-098224

Alert Tier

5